A man living with an incurable blood cancer is aiming to raise awareness of the symptoms to make sure others are spared the ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

The family of a man employed in the maintenance department of the Pleasant Valley School District stricken with a rare blood and bone cancer will be among several beneficiaries of a fundraiser held ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Researchers conducted an analysis of how NCCN guidelines for myeloma treatment are updated, offering suggestions for a more standardized process.

In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always ...

This year's fallen firefighter memorial service is set for Sunday at 10 a.m. in Phoenix, according to Professional Fire ...

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world ...

“We believe that specifically targeting these two RANK motifs has the potential to serve as effective and selective therapeutic targets for bone lesions in multiple myeloma.” The R21 grant supporting ...

Forty-eight patients with multiple myeloma, most of them ambulatory outpatients ... osteolytic lesions and bone-marrow plasmacytosis). 7 The disease was classified as in partial remission ...

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...